Content about Reddy

HYDERABAD, India — Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

The drug, launched following its approval by the Food and Drug Administration, is a generic version of Novartis' Reclast and is used to treat osteoporosis. Reclast had sales of $355 million during the 12-month period that ended in February, according to IMS Health.

HYDERABAD, India — Dr. Reddy's has launched a drug for treating acne, the company said Friday.

The Indian generic drug maker announced the launch of Zenatane (isotretinoin) capsules in the 20-mg and 40-mg strengths. The drug is a therapeutically equivalent generic version of Roche's Accutane. The Food and Drug Administration also approved the drug in the 10-mg strength.

Various versions of the drug had sales of about $309 million during the 12-month period that ended in January, according to IMS Health.

 SILVER SPRING, Md. - The Food and Drug Administration has given tentative approval to a generic drug for treating hypertension, according to agency records.

The FDA granted tentative approval to Dr. Reddy's Labs' valsartan tablets in the 40 mg, 80 mg, 160 mg and 320 mg strengths.

The drug is a generic version of Novartis' Diovan. Various versions of the drug had sales of $1.6 billion during the 12-month period that ended in June, according to IMS Health.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

Dr. Reddy's announced the launch of finasteride tablets in the 1-mg strength, a generic version of Merck's Propecia. As the first company to successfully file for approval of a generic version of the drug, Dr. Reddy's is entitled to 180 days of market exclusivity in which to compete directly with the branded version.

Propecia had sales of about $136 million during the 12-month period that ended in October 2012, according to IMS Health.

Dr. Reddy's launches antibiotics

HYDERABAD, India — Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

The India-based company announced the launch of amoxicillin tablets, capsules and oral suspension. The tablets are being launched in the 500-mg and 875-mg strengths, while the capsules are in the 250-mg and 500-mg strengths, and the oral suspension is in the 125-mg-, 200-mg-, 250-mg- and 400-mg-per-5-mL strengths.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic drug for treating high blood pressure, the company said.

Dr. Reddy's announced the launch of metoprolol succinate extended-release tablets in the 25-mg, 50-mg, 100-mg and 200-mg strengths. The drug will be available in bottle counts of 100 and 500.

The drug is a generic version of AstraZeneca's Toprol-XL, branded and generic versions of which had sales of about $1.13 billion during the 12-month period that ended in June, according to IMS Health.

HYDERABAD, India — Dr. Reddy's has launched a drug designed to prevent and treat osteoporosis.

The generic drug maker launched ibandronate sodium tablets in the 150-mg strength, following approval by the Food and Drug Administration for the drug maker's abbreviated new drug application. The drug is a generic version of Boniva.

The branded drug and generic versions had U.S. sales of approximately $486 million during the 12-month period ended in March, according to IMS Health.

HYDERABAD, India — A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

Dr. Reddy's Labs and Merck KGaA subsidiary Merck Serono announced a partnership to develop biosimilar cancer treatments, most of them monoclonal antibodies, for global markets. Based in Darmstadt, Germany, Merck KGaA operates in the United States under the name EMD to distinguish itself from U.S. drug maker Merck.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

Dr. Reddy's announced Friday the launch of clopidogrel tablets in the 75-mg and 300-mg strengths. The drug is a generic version of Plavix, made by Bristol-Myers Squibb and Sanofi. As one of the first companies to submit a completed regulatory application for the 300 mg strength of the drug, Dr. Reddy's received 180 days of market exclusivity for it.

NEW YORK — Three companies have launched generic versions of a psychiatric drug made by AstraZeneca following a court decision turning down the Anglo-Swedish drug maker's request for an injunction against the Food and Drug Administration's approval of the generics.

Dr. Reddy's Labs, Teva and Mylan announced Wednesday the launch of their respective versions of quetiapine fumarate tablets, generic formulations of AstraZeneca's Seroquel, in strengths ranging from 25 mg to 400 mg.

With the patent cliff and subsequent innovation drought moving closer, generic drug makers are looking to move up the value chain and pursue new sources of revenue, and of all the piles of pay dirt out there, biosimilars represent one of the closest things to an El Dorado, though regulations won’t take their final form for a while.